Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 4/20 | 0.47 |
| ▸ | CTSA | P10619 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 3/20 | 0.41 |
| ▸ | DCAF1 | Q9Y4B6 | 2/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.40 |
| ▸ | EEF2K | O00418 | 1/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926574 | 0.85 | CCKAR (0.49) | KCNA5KDM4E | |
| SCHEMBL5926355 | 0.84 | CTSA (0.46) | KCNA5CTSAACLYCYP26A1MMP12 | |
| SCHEMBL5926476 | 0.83 | ACLY (0.52) | KCNA5CTSAACLYCYP26A1 | |
| SCHEMBL5926378 | 0.81 | KCNA5 (0.47) | KCNA5CTSA | |
| SCHEMBL5926687 | 0.81 | KCNA5 (0.49) | KCNA5ACLYCYP26A1EEF2K | |
| SCHEMBL5927111 | 0.80 | ACLY (0.52) | KCNA5CTSAACLYCYP26A1 | |
| SCHEMBL8337865 | 0.80 | CCKAR (0.51) | KCNA5 | |
| SCHEMBL6098358 | 0.79 | METAP2 (0.49) | KCNA5CTSA | |
| SCHEMBL5926310 | 0.79 | METAP2 (0.49) | KCNA5CTSA | |
| SCHEMBL5926538 | 0.76 | ACLY (0.50) | KCNA5ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | KCNA5 1021/4885CTSA 426/4885KDM4E 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.